Spacer length shapes drug release and therapeutic efficacy of traceless disulfide-linked ADCs targeting the tumor neovasculature

Influence of DOTA Chelator Position on Biodistribution and Targeting Properties of 111In-Labeled Synthetic Anti-HER2 Affibody Molecules

(2012) Anna Perols et al.   BIOCONJUGATE CHEMISTRY

Fucose-specific conjugation of hydrazide derivatives to a vascular-targeting monoclonal antibody in IgG format

(2012) Kathrin Zuberbühler et al.   CHEMICAL COMMUNICATIONS

The Antibody-Based Delivery of Interleukin-12 to the Tumor Neovasculature Eradicates Murine Models of Cancer in Combination with Paclitaxel

(2012) N. Pasche et al.   CLINICAL CANCER RESEARCH

Antibody–drug conjugates: Basic concepts, examples and future perspectives

(2012) Giulio Casi et al.   JOURNAL OF CONTROLLED RELEASE

Site-Specific Traceless Coupling of Potent Cytotoxic Drugs to Recombinant Antibodies for Pharmacodelivery

(2012) Giulio Casi et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates

(2012) Mauro Acchione et al.   mAbs

The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

(2012) Peter D Senter et al.   NATURE BIOTECHNOLOGY

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates

(2012) Ben-Quan Shen et al.   NATURE BIOTECHNOLOGY

A “Tag-and-Modify” Approach to Site-Selective Protein Modification

(2011) Justin M. Chalker et al.   ACCOUNTS OF CHEMICAL RESEARCH

Selenenylsulfide-Linked Homogeneous Glycopeptides and Glycoproteins: Synthesis of Human “Hepatic Se Metabolite A”

(2011) Omar Boutureira et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

A Traceless Vascular-Targeting Antibody-Drug Conjugate for Cancer Therapy

(2011) Gonçalo J. L. Bernardes et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Disulfide-Linked Antibody−Maytansinoid Conjugates: Optimization of In Vivo Activity by Varying the Steric Hindrance at Carbon Atoms Adjacent to the Disulfide Linkage

(2011) Brenda A. Kellogg et al.   BIOCONJUGATE CHEMISTRY

Tunable Degradation of Maleimide–Thiol Adducts in Reducing Environments

(2011) Aaron D. Baldwin et al.   BIOCONJUGATE CHEMISTRY

A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels

(2011) A Palumbo et al.   BRITISH JOURNAL OF CANCER

Interplay of Chemical Microenvironment and Redox Environment on Thiol-Disulfide Exchange Kinetics

(2011) Chuanliu Wu et al.   CHEMISTRY-A EUROPEAN JOURNAL

The antibody-mediated targeted delivery of interleukin-10 inhibits endometriosis in a syngeneic mouse model

(2011) Kathrin Schwager et al.   HUMAN REPRODUCTION

Combination Radioimmunotherapy and Chemoimmunotherapy Involving Different or the Same Targets Improves Therapy of Human Pancreatic Carcinoma Xenograft Models

(2011) R. M. Sharkey et al.   MOLECULAR CANCER THERAPEUTICS

Methods for converting cysteine to dehydroalanine on peptides and proteins

(2011) Justin M. Chalker et al.   Chemical Science

Comparative in vivo analysis of the atherosclerotic plaque targeting properties of eight human monoclonal antibodies

(2010) Michael Fiechter et al.   ATHEROSCLEROSIS

Physicochemical Stability of the Antibody−Drug Conjugate Trastuzumab-DM1: Changes due to Modification and Conjugation Processes

(2010) Aditya A. Wakankar et al.   BIOCONJUGATE CHEMISTRY

Antibody–drug conjugates: targeted drug delivery for cancer

(2010) Stephen C Alley et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Chemical mutagenesis: selective post-expression interconversion of protein amino acid residues

(2010) Justin M Chalker et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

(2010) Howard A. Burris et al.   JOURNAL OF CLINICAL ONCOLOGY

Antibody drug-conjugates targeting the tumor vasculature

(2010) Hans-Peter Gerber et al.   mAbs

Disulfide-directed histone ubiquitylation reveals plasticity in hDot1L activation

(2010) Champak Chatterjee et al.   Nature Chemical Biology

Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas

(2010) Anas Younes et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients

(2009) S. Sauer et al.   BLOOD

Potent antibody drug conjugates for cancer therapy

(2009) Peter D Senter   CURRENT OPINION IN CHEMICAL BIOLOGY

From Disulfide- to Thioether-Linked Glycoproteins

(2008) Gonçalo J. L. Bernardes et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2

(2008) C. Schliemann et al.   BLOOD

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate

(2008) G. D. Lewis Phillips et al.   CANCER RESEARCH

A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculaturein vivo

(2008) Alessandra Villa et al.   INTERNATIONAL JOURNAL OF CANCER

Facile Conversion of Cysteine and Alkyl Cysteines to Dehydroalanine on Protein Surfaces: Versatile and Switchable Access to Functionalized Proteins

(2008) Gonçalo J. L. Bernardes et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Chemical site-selective prenylation of proteins

(2008) David P. Gamblin et al.   Molecular BioSystems

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

(2008) Jagath R Junutula et al.   NATURE BIOTECHNOLOGY

Targeted Cancer Therapy: Conferring Specificity to Cytotoxic Drugs

(2007) Ravi V. J. Chari   ACCOUNTS OF CHEMICAL RESEARCH